Editorial
|
|
|
|
|
Patient empowerment and publicly-funded research
|
|
|
|
Marketing Authorisations
|
|
|
|
|
Uncertain harm-benefit balance
|
|
|
|
|
|
|
|
|
|
|
|
Two new drugs, but no progress
|
|
|
|
|
|
|
|
|
|
Useful for some patients in treatment failure
|
|
|
|
|
|
|
|
|
|
New oral transmucosal form has no advantages in breakthrough pain
|
|
|
|
|
|
|
|
|
|
Adverse Effects
|
|
|
|
|
Beware of overuse
|
|
|
|
|
|
|
|
|
|
Certainly not a safe drug
|
|
|
|
|
|
|
|
|
|
Dehydration is a contributing factor
|
|
|
|
|
|
|
|
|
|
|
|
Carefully assess harm-benefit balance in cirrhosis patients
|
|
|
|
|
|
|
|
|
|
Unfavourable harm-benefit balance
|
|
|
|
|
|
|
|
|
|
How many more victims before market withdrawal?
|
|
|
|
|
|
|
|
|
|
Informing patients is key
|
|
|
|
|
|
|
|
|
|
|
|
Assess risk of serious bleeding before use
|
|
|
|
Reviews
|
|
|
|
|
Vague and irrelevant concepts
|
|
|
|
|
|
|
|
|
|
Leukaemia patients are also at risk
|
|
|
|
|
|
|
|
|
|
Poorly effective, potentially harmful
|
|
|
|
|
|
|
|
|
|
Especially relevant for young patients
|
|
|
|
|
|
|
|
|
|
|
|